Health

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

October 22, 2025 16:30 ET  | Source: CVRx, Inc. MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)…

8 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease

October 22, 2025 16:30 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

8 months ago

Aveanna Announces Pricing of Secondary Offering of Common Stock

ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused…

8 months ago

Biomea Fusion to Participate in Citi’s SMID Biotech C-Suite Fireside Chat Series

October 21, 2025 19:05 ET  | Source: Biomea Fusion, Inc. SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea…

8 months ago

Sotera Health Announces Third-Quarter 2025 Earnings Release Date

CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization…

8 months ago

PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared…

8 months ago

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…

8 months ago

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Companys Ongoing Transformation

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable…

8 months ago

IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

October 20, 2025 02:30 ET  | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…

8 months ago

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…

8 months ago